Table 2.

Univariate analysis of metastatic PCa.

Variate	No.	Progression-free survival			Overall survival
		HR	95% CI	p value	HR	95% CI	p value
Age (per 1 year)
		1.002	0.976-1.029	0.850	1.014	0.979-1.051	0.439
Gleason score
≤6	5	1			1
7	29	9.49 E+08	0.980-infinity	0.052	3.97 E+08	0.569-infinity	0.130
≥8	129	1.70 E+09	1.840-infinity	0.008	5.80 E+08	0.899-infinity	0.062
PSA at diagnosis (per 1 ng/ml)
		1	0.999-1.000	0.128	1	0.999-1.000	0.237
cT stage
T1c T2a T2b T2c	11	1			1
T3a T3b	107	1.802	0.664-7.405	0.277	4.73 E+08	1.543-infinity	0.015
T4	52	3.392	1.221-14.082	0.015	7.56 E+08	2.432-infinity	0.003
cN stage
N0	59	1			1
N1	116	1.443	0.939-2.277	0.095	1.104	0.646-1.941	0.720
cM stage
M0	19	1			1
M1	157	2.365	1.125-6.079	0.020	2.111	0.856-7.032	0.112
Testosterone (per 1 ng/dl)		1.001	0.998-1.003	0.388	1.001	0.998-1.004	0.442
Visceral fat percentage (per 1%)		0.979	0.965-0.994	0.006	0.979	0.961-0.997	0.029
V/S ratio (per 1)		1.010	0.975-1.029	0.446	1.009	0.921-1.038	0.722
Psoas muscle ratio (per 1 cm3/cm)		1.109	0.729-1.651	0.901	0.593	0.316-1.066	0.082
BMI (per 1 kg/m2)		0.943	0.881-1.007	0.084	0.883	0.802-0.968	0.007

Abbreviations: BMI, body mass index;PSA, prostate-specific antigen; V/S ratio, Visceral fat/subcutaneous fat ratio.